Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma

被引：0

作者：

Luo, Fei ^{[1
,2
]}

Zhong, Qiu-Zi ^{[3
]}

Liu, Xin ^{[1
]}

Hou, Xiao-Rong ^{[4
]}

Qian, Li-Ting ^{[5
]}

Qiao, Xue-Ying ^{[6
]}

Wang, Hua ^{[7
]}

Zhu, Yuan ^{[8
]}

Cao, Jian-Zhong ^{[9
,10
]}

Wu, Jun-Xin ^{[11
]}

Wu, Tao ^{[12
]}

Zhu, Su-Yu ^{[13
,14
]}

Shi, Mei ^{[15
]}

Zhang, Hui-Lai ^{[16
]}

Zhang, Xi-Mei ^{[16
]}

Su, Hang ^{[17
]}

Song, Yu-Qin ^{[18
]}

Zhu, Jun ^{[18
]}

Zhang, Yu-Jing ^{[19
]}

Huang, Hui-Qiang ^{[19
]}

Wang, Ying ^{[20
,21
]}

He, Xia ^{[22
,23
]}

Zhang, Li-Ling ^{[24
]}

Qu, Bao-Lin ^{[25
]}

Yang, Yong ^{[26
]}

Hu, Chen ^{[27
]}

Deng, Min ^{[1
]}

Wang, Shu-Lian ^{[1
]}

Qi, Shu-Nan ^{[1
]}

Li, Ye-Xiong ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Radiat Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, 17 Panjiayuan Rd, Beijing 100021, Peoples R China

[2] Capital Med Univ, Beijing Shijitan Hosp, Dept Radiat Oncol, Beijing, Peoples R China

[3] Beijing Hosp, Natl Geriatr Med Ctr, Dept Radiat Oncol, Beijing, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China

[5] Anhui Med Univ, Affiliated Prov Hosp, Hefei, Anhui, Peoples R China

[6] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China

[7] Second Affiliated Hosp Nanchang Univ, Nanchang, Peoples R China

[8] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Canc & Basic Med ,Canc Hosp, Hangzhou, Zhejiang, Peoples R China

[9] Shanxi Med Univ, Shanxi Canc Hosp, Taiyuan, Shanxi, Peoples R China

[10] Shanxi Med Univ, Affiliated Canc Hosp, Taiyuan, Shanxi, Peoples R China

[11] Fujian Prov Canc Hosp, Fuzhou, Fujian, Peoples R China

[12] Guizhou Med Univ, Guizhou Canc Hosp, Affiliated Hosp, Guiyang, Peoples R China

[13] Xiangya Sch Med, Hunan Canc Hosp, Changsha, Hunan, Peoples R China

[14] Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Hunan, Peoples R China

[15] Fourth Mil Med Univ, Xijing Hosp, Xian, Peoples R China

[16] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China

[17] Fifth Med Ctr PLA Gen Hosp, Beijing, Peoples R China

[18] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China

[19] Sun Yat sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[20] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China

[21] Chongqing Canc Hosp, Chongqing, Peoples R China

[22] Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China

[23] Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China

[24] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China

[25] Gen Hosp Chinese Peoples Liberat Army, Beijing, Peoples R China

[26] Fujian Med Univ, Union Hosp, Dept Radiat Oncol, Fuzhou, Fujian, Peoples R China

[27] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Div Biostat & Bioinformat, Baltimore, MD USA

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2024年 / 16卷

关键词：

combination therapy; drug; NK/T-cell lymphoma; radiotherapy; NASAL-TYPE; RADIATION-THERAPY; GEMCITABINE; SURVIVAL; OUTCOMES; IMMUNOTHERAPY; DEXAMETHASONE; MULTICENTER; CISPLATIN; EFFICACY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Extranodal natural killer/T-cell lymphoma (ENKTCL) has a unique treatment principle. However, the optimal combination of drugs along with radiotherapy (RT) is unknown. Design: Retrospective cohort study. Objectives: We screened multiple drug combinations to identify the most efficacious therapeutic combinations. Methods: We reviewed 3105 patients who received 40 chemotherapy regimens with different combinations of 9 drug classes and/or RT. Least absolute shrinkage and selection operator and multivariable Cox regression analyses were used to screen efficacious single drugs and identify optimal combinations for overall survival (OS). Inverse probability of treatment weighting (IPTW) and multivariable analyses were used to compare survival between treatment regimens. Results: Screening and validation revealed RT, asparaginase (ASP), and gemcitabine (GEM) to be the most efficacious single modality/drug. RT remained an important component of first-line treatment, whereas ASP was a fundamental drug of non-anthracycline (ANT)-based regimens. Addition of RT to non-ANT-based or ASP/GEM-based regimens, or addition of an ASP-drug into ANT-based or GEM/platinum-based regimens, improved 5-year OS significantly. Use of ASP/GEM-based regimens was associated with significantly higher 5-year OS (79.9%) compared with ASP/ANT-based (69.2%, p = 0.001), ASP/methotrexate-based (63.5%, p = 0.011), or ASP/not otherwise specified-based (63.2%, p < 0.001) regimens. The survival benefit of ASP/GEM-based regimens over other ASP-based regimens was substantial across risk-stratified and advanced-stage subgroups. The survival benefits of a combination of RT, ASP, and GEM were consistent after adjustment for confounding factors by IPTW. Conclusion: These results suggest that combining ASP/GEM with RT for ENKTCL is an efficacious and feasible therapeutic option and provides a rationale and strategy for developing combination therapies.

引用

页数：16

共 50 条

[1] Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma
Luo, Fei
Zhong, Qiu-Zi
Liu, Xin
Hou, Xiao-Rong
Qian, Li-Ting
Qiao, Xue-Ying
Wang, Hua
Zhu, Yuan
Cao, Jian-Zhong
Wu, Jun-Xin
Wu, Tao
Zhu, Su-Yu
Shi, Mei
Zhang, Hui-Lai
Zhang, Xi-Mei
Su, Hang
Song, Yu-Qin
Zhu, Jun
Zhang, Yu-Jing
Huang, Hui-Qiang
Wang, Ying
He, Xia
Zhang, Li-Ling
Qu, Bao-Lin
Yang, Yong
Hu, Chen
Deng, Min
Wang, Shu-Lian
Qi, Shu-Nan
Li, Ye-Xiong
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[2] Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents
Zhen, Zijun
Huang, Huiqiang
Lin, Tongyu
Li, Zhiming
Zhen, Xi
Xia, Zhongjun
Zhu, Jia
Lu, Suying
Sun, Feifei
Wang, Juan
Huang, Junting
Sun, Xiaofei
PEDIATRIC BLOOD & CANCER, 2021, 68 (05)
[3] The landscape of new drugs in extranodal NK/T-cell lymphoma
Wang, Liang
Li, Lin-Rong
Zhang, Luo
Wang, Jing-Wen
CANCER TREATMENT REVIEWS, 2020, 89
[4] A prospective study of chemoradiotherapy for early stage extranodal natural killer (NK)/T-cell lymphoma
Zhou, Fei
Xue, Hongwei
Zhao, Yanwei
Liu, Xiaoran
Dong, Qing
Yu, Hongsheng
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 14397 - 14403
[5] Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma
Terro, Khodr
Sharrouf, Layal
El Cheikh, Jean
FRONTIERS IN ONCOLOGY, 2022, 12
[6] Extranodal NK/T cell lymphoma
Jeong, Seong Hyun
BLOOD RESEARCH, 2020, 55 : 63 - 71
[7] New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma
Yi, Wu
Yang, Tianxin
Lin, Sisi
Hao, Rui
Yu, Jin
Wang, Ying
Tong, Xiangming
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 401 - 407
[8] Extranodal NK/T-cell lymphoma: Updates in biology and management strategies
Yamaguchi, Motoko
Oguchi, Masahiko
Suzuki, Ritsuro
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (03) : 315 - 321
[9] Cutaneous Peripheral T-Cell Lymphoma of Cytotoxic Phenotype Mimicking Extranodal NK/T-Cell Lymphoma
Pan, Shien-Tung
Chang, Wen-Sen
Murphy, Michael
Martinez, Antonio
Chuang, Shih-Sung
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2011, 33 (02) : E17 - E20
[10] An autopsy case of primary extranodal NK/T cell lymphoma (extranodal NK/T-cell lymphoma) of the bile duct
Ito, Hiroyuki
Hiraiwa, Shin-ichiro
Sugiyama, Tomoko
Tajiri, Takuma
Yamaji, Yoko
Kaneko, Motoki
Tsuda, Shingo
Ichikawa, Hitoshi
Nagata, Junko
Kojima, Seiichiro
Takashimizu, Shinji
Shirai, Takayuki
Watanabe, Norihito
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2019, 12 (03) : 209 - 212

← 1 2 3 4 5 →